The FDA has issued a Complete Response Letter for Mylan and Biocon’s pegfilgrastim biosimilar, MYL-1401H, referenced on Neulasta.
Indian drug maker Biocon announced today that the FDA has issued a Complete Response Letter (CRL) for Biocon—Mylan’s proposed pegfilgrastim biosimilar, MYL-1401H, referenced on Neulasta.
Pegfilgrastim is a long-acting version of filgrastim; while biosimilars of filgrastim are approved in the United States and in the European Union, to date, no biosimilar developer had been successful in gaining regulatory clearance in either region for the more complex long-acting drug. One of the challenges of developing pegfilgrastim has been the presence of the polyethylene glycol (PEG) molecule, which is bonded to filgrastim and slows the rate at which the drug is metabolized.
Biocon indicates that the CRL for the drug relates to “data from facility requalification activities” after recent modifications to its manufacturing plant, and that the CRL did not raise questions concerning the drug’s biosimilarity, pharmacokinetic or pharmacodynamic data, clinical data, or immunogenicity. Biocon—Mylan had previously withdrawn an application for the same drug from the European Medicines Agency (EMA) after a French National Agency for Medicines and Health Products Safety (ANSM) inspection that found 35 deficiencies—11 of them major—in Biocon’s manufacturing practices at its Bangalore manufacturing plant. While the companies plan to resubmit their application to the EMA after a re-inspection of the facility, they have not issued a statement as to when they plan to resubmit a Biologics License Application for the drug to the FDA.
Some stakeholders are hopeful that an eventual approval of a biosimilar pegfilgrastim could produce significant savings for health plans. Molly Billstein Leber, PharmD, BCPS, FASHP, and manager of medication policy and formulary management for the Yale New Haven Health System, told The Center for Biosimilars® in an e-mail, “If insurance companies will reimburse for the biosimilar product, it will be a huge cost savings to the health system. The majority of pegfilgrastim usage is outpatient, so the acceptance rate will be closely tied to reimbursement.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.